The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
Two new pivotal Chinese first-line trials have started in lung cancer.
The company takes a PD-L1 x VEGF asset into phase 3.
